TiumBio Co. Ltd (321550) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of TiumBio Co. Ltd KRW 887, price KRW 4,220, upside -79.0%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604.
Show more
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.
Stock analysis
TiumBio Co. Ltd (321550) currently trades at 4,220 KRW, while our model-based Fair Value estimate is 887.12 KRW, 79.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 90/100, which puts the evidence level at low.
Scenario range: 662.03 KRW (bear) to 1,324 KRW (bull), the price of 4,220 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
TiumBio Co. Ltd reported revenue of 12.3B KRW in FY2025 versus 56.8M KRW in FY2021, a compound +283.5%/yr. Reported net income was −17.4B KRW in FY2025.
Key figures
Market cap 133B KRW (≈ $99.1M) · P/S ratio 8.87 · Net margin −141% · Return on equity −36.7% · Return on assets (EBIT) −17.7% · Operating margin −94.8% · Revenue (TTM) 15.0B KRW · Revenue growth (YoY) +71.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 68% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −79%, 321550 screens richer than that median.
Fair Value models
Bear 662.03 KRWFair Value 887.12 KRWBull 1,324 KRW
Price 4,220 KRW · Upside -79.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+80.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.8%
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,268.3% (2020) → −131.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 590 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−79.0% · Bottom 25%
Profitability
Return on assets−10.1% · Below median
Net margin (TTM)−114.1% · Bottom 25%
Operating margin (TTM)−94.8% · Bottom 25%
Growth and dividend
Revenue growth71.3% · Top 25%
Balance sheet
Debt / equity0.33× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)84· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is TiumBio Co. Ltd (321550) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 887.12 KRW versus a price of 4,220 KRW, about −79% upside (overvalued).
What is the fair value of 321550?
Our model-based fair value for TiumBio Co. Ltd is 887.12 KRW (as of Oct 4, 2026), built from audited fundamentals. The current price: 4,220 KRW.
What is the quality score of 321550?
TiumBio Co. Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TiumBio Co. Ltd (321550)?
Our model-based price target is the fair value of 887.12 KRW (as of Oct 4, 2026) from 1 valuation models. Cautious scenario 662.03 KRW, optimistic scenario 1,324 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the TiumBio Co. Ltd stock forecast for 2026?
Our models put fair value at 887.12 KRW, about −79% upside versus a price of 4,220 KRW (overvalued). Cautious scenario 662.03 KRW, optimistic scenario 1,324 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of TiumBio Co. Ltd (321550)?
TiumBio Co. Ltd reported trailing-twelve-month revenue of about 15.0B KRW (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of TiumBio Co. Ltd (321550)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TiumBio Co. Ltd it is 887.12 KRW per share (as of Oct 4, 2026), against a price of 4,220 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TiumBio Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 321550 trades above its calculated fair value: price 4,220 KRW, fair value 887.12 KRW, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 321550?
No. The price is what the market pays today (4,220 KRW); the fair value is what the company's own numbers justify (887.12 KRW). For TiumBio Co. Ltd the two are 3,333 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is TiumBio Co. Ltd worth?
The market values TiumBio Co. Ltd at about 133B KRW (market capitalisation, as of Oct 4, 2026). Per share that is 4,220 KRW; our models calculate a fair value of 887.12 KRW per share.
What do the bullish and bearish scenarios say about 321550?
Our models span a range for TiumBio Co. Ltd: cautious scenario 662.03 KRW, base 887.12 KRW, optimistic 1,324 KRW per share (as of Oct 4, 2026, price 4,220 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TiumBio Co. Ltd (321550)?
Balance-sheet figures for TiumBio Co. Ltd (as of Oct 4, 2026): return on equity −36.7%, debt of 0.33 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 321550 from its 52-week high?
TiumBio Co. Ltd trades at 4,220 KRW, about 68% below its 52-week high of 13,140 KRW and 15% above the low of 3,680 KRW (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of 887.12 KRW is for.
Which stocks are comparable to TiumBio Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TiumBio Co. Ltd stock attractive at the current price?
The data as of Oct 4, 2026: price 4,220 KRW, calculated fair value 887.12 KRW (−79%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 321550 calculated?
We run TiumBio Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 887.12 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. TiumBio Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TiumBio Co. Ltd (321550)?
The closing price on Oct 12, 2026 was 4,220 KRW. Our model-based fair value is 887.12 KRW, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TiumBio Co. Ltd right now?
The price sits above even our optimistic bull case (1,324 KRW). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (662.03 KRW to 1,324 KRW) leaves room in how you read the outcome.
Key figures of TiumBio Co. Ltd
How large is the market capitalisation of TiumBio Co. Ltd (321550)?
The market capitalisation of TiumBio Co. Ltd is 133B KRW (≈ $99.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TiumBio Co. Ltd (321550)?
The price-to-sales ratio of TiumBio Co. Ltd is 8.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of TiumBio Co. Ltd (321550)?
The net margin of TiumBio Co. Ltd is −141% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TiumBio Co. Ltd (321550)?
The return on equity (ROE) of TiumBio Co. Ltd is −36.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TiumBio Co. Ltd (321550)?
On an EBIT basis the return on assets of TiumBio Co. Ltd is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TiumBio Co. Ltd (321550)?
The operating margin of TiumBio Co. Ltd is −94.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TiumBio Co. Ltd (321550)?
Revenue at TiumBio Co. Ltd is growing +71.3% versus a year earlier (3y avg +10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TiumBio Co. Ltd (321550)?
Earnings per share at TiumBio Co. Ltd are growing −12.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does TiumBio Co. Ltd (321550) generate?
The free cash flow of TiumBio Co. Ltd is −15.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does TiumBio Co. Ltd (321550) carry?
The net debt of TiumBio Co. Ltd is 19.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch TiumBio Co. Ltd in the live analysis
One click puts TiumBio Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
